Dr. Woyach on Ibrutinib Resistance in CLL

(1:47)

Dr. Woyach on the Safety of Acalabrutinib Versus Ibrutinib in CLL

(1:3)

Dr. Woyach on the Role of Acalabrutinib in CLL

(1:39)

Dr. Woyach on Treatment Challenges in CLL

(1:17)

Dr. Woyach Discusses Peripheral Lymphocytosis in Patients with CLL Taking Ibrutinib

(1:26)

Dr. Woyach on Ibrutinib and Peripheral Lymphocytosis in Patients with Chronic Lymphocytic Leukemia

(1:16)

Cystoid Macular Edema

(1:52:35)

SDB Ethel Browne Harvey Postdoctoral Seminar Series - Yuchuan Miao and Kari Price

(57:35)

Jennifer Woyach, MD, Highlights Novel CLL Therapies Presented at ASH 2023

(9:47)

Carol Moreno, MD, PhD, shares outcomes from the iLLUMINATE trial presented at ASH 2018

(1:3)

Horsehair Nematomorpha Human Parasite - Morgellons - Clinging On

(4:44)

UofL Dept. of Medicine Research Grand Rounds: Dr. Leslie Wolf Parrish

(44:43)

Safety of Dual Covalent and Noncovalent BTK Inhibitor for CLL - ASH 2023 Dr. Jennifer Woyach

(4:39)

Dr. Woyach on the Role of Chemoimmunotherapy in CLL

(1:25)

Dr. Woyach on the Role of Small Molecule Inhibitors in CLL

(1:8)

Dr. Woyach on Ibrutinib Regimens in Frontline CLL

(1:6)

Dr. Woyach Discusses Progression on Ibrutinib With the Acquisition of Resistance Mutations

(1:17)

Dr. Woyach Discusses Efficacy Findings from the RESONATE Trial

(40)

Dr. Woyach on Clinical Trials Examining Novel Triplets in CLL

(1:21)

Dr. Woyach on BTK Inhibition and the Mechanism of Action of Ibrutinib

(1:17)

Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial

(28)

Dr. Woyach on Using Ibrutinib in Combination Therapies

(1:53)

Dr. Woyach Discusses Progression on Ibrutinib With the Acquisition of Resistance Mutations

(1:31)

Dr. Woyach on 3-Year Follow-Up of Acalabrutinib/Obinutuzumab Combo in CLL

(1:20)

Dr. Woyach on the Results of the ELEVATE-TN Trial

(55)

Dr. Woyach on Preliminary Efficacy Results of MOR208 Trial in CLL

(49)